Recent Updates — SXTC
China SXT Pharmaceuticals has entered into a termination letter agreement to fully terminate the additional purchase right (over-allotment option) associated with its registered direct offering announced on October 8, 2026. This right had permitted investors to acquire up to an additional $12 million of Class A ordinary shares and pre-funded warrants within 30 days of the initial closing. The termination means purchasers no longer have any entitlement to make these additional purchases, though all other provisions of the original securities purchase agreement remain in full force. The company operates as an innovative pharmaceutical firm focusing on the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces.
China SXT Pharmaceuticals, Inc. closed a registered direct offering on October 9, 2026, selling 8,000,000 units to investors for gross proceeds of approximately $12,000,000. Each unit consists of one Class A ordinary share or pre-funded warrant and one ordinary warrant exercisable at $2.75 per share until October 9, 2027. The company engaged Univest Securities, LLC as placement agent for a 7% fee plus expenses. The offering includes an over-allotment option to raise an additional $12,000,000 within 30 days of closing. China SXT Pharmaceuticals, Inc. operates in the pharmaceutical industry.
China SXT Pharmaceuticals announced a definitive agreement with institutional investors for a registered direct offering of up to 8,000,000 Class A ordinary shares (or pre-funded warrants) at $1.50 per share, generating approximately $12 million in gross proceeds. The company will also issue 8,000,000 common warrants exercisable at $2.75 per share for a one-year term. Investors hold an additional purchase right to acquire up to another $12 million of securities within 30 days after closing. The offering is expected to close on or about October 9, 2026, subject to customary conditions. China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.
On October 7, 2026, China SXT Pharmaceuticals entered into a Securities Purchase Agreement for a private placement of 3 million Class A ordinary shares and warrants to purchase an additional 3 million shares. The offering was intended to raise $3 million in gross proceeds from non-U.S. persons under Regulation S. However, on October 8, 2026, the company and the purchasers agreed to terminate the agreement prior to closing. No shares or warrants were issued, and all obligations under the Securities Purchase Agreement were terminated. China SXT Pharmaceuticals operates in the pharmaceutical industry.
China SXT Pharmaceuticals, Inc. entered into an amendment to its Securities Purchase Agreement with institutional investors on August 27, 2026. The company previously executed a 1-for-80 share consolidation effective August 10, 2026, which adjusted the floor price for pre-paid purchases from $0.20 to $16.00 per share. The amendment reduced this floor price back to $0.20 per share while maintaining an aggregate principal amount of up to $31,500,000. This transaction involves the issuance and sale of Class A ordinary shares. China SXT Pharmaceuticals operates in the pharmaceutical industry, focusing on the research, development, and manufacturing of drugs.